Denosumab Treatment for Giant Cell Tumor of the Spine Including the Sacrum
Authors:
Open Access
- 8 October 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Spine
- Vol. 46 (5) , 277-284
Abstract
Study Design.: This was a subanalysis of an international, multicenter, open-label study. Objective.: The aim of this study was to assess the efficacy and safety of denosumab in a subset of patients with giant cell tumors of bone (GCTB) of the spine including the sacrum from an international, open-label, single-arm, phase 2 study (ClinicalTrials.gov: NCT00680992). Summary of Background Data.: Standard GCTB treatment is surgical removal, either by curettage or resection, combined with intraoperative adjuvant therapy; however, some sites may not be amenable to resection (e.g., skull, spine). Methods.: Adults or skeletally mature adolescents with pathologically confirmed GCTB of the spine including the sacrum, and radiologically measurable evidence of active disease, were included. Patients received denosumab (120 mg subcutaneously) once every 4 weeks during the treatment phase, with loading doses on days 8 and 15 of the first cycle. Patients had surgically unsalvageable GCTB (Cohort 1), had planned surgery expected to result in severe morbidity (Cohort 2), or were enrolled from a previous GCTB study (Cohort 3). Results.: Overall, 132 patients were included in the safety analysis (103 in Cohort 1, 24 in Cohort 2, and five in Cohort 3); 131 patients were included in the efficacy analysis. Kaplan-Meier estimated probabilities of disease progression or recurrence were 3% (95% confidence interval [CI], 0.0–6.2) at year 1 and 7.4% (95% CI, 2.1–12.7) at years 3 and 5 in Cohort 1, and not estimable in Cohorts 2 and 3. Of 23 patients (Cohort 2) with surgery planned at baseline, 10 (43%) had on-study surgery; of these, one patient had reported disease progression or recurrence after the on-study surgery. Clinical benefit was reported in 83% of patients overall (all cohorts). Conclusion.: Results from the analysis suggest that denosumab is potentially effective treatment for patients with GCTB of the spine including the sacrum. The adverse event profile was consistent with the full study population. Level of Evidence: 2Keywords
This publication has 18 references indexed in Scilit:
- Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 studyThe Lancet Oncology, 2013
- Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of BoneClinical Cancer Research, 2012
- Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple MyelomaJournal of Clinical Oncology, 2011
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind studyThe Lancet, 2011
- Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind StudyJournal of Clinical Oncology, 2010
- Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 studyThe Lancet Oncology, 2010
- Giant Cell Tumor of BoneOrthopedic Clinics of North America, 2006
- Gene expression in giant-celltumorsJournal of Laboratory and Clinical Medicine, 2004
- Mechanisms of Bone MetastasisNew England Journal of Medicine, 2004
- Long‐term follow‐up of patients with giant cell tumor of the sacrum treated with selective arterial embolizationCancer, 2002